Loading...
High efficient adenoviral-mediated VEGF and Ang-1 gene delivery into osteogenically differentiated human mesenchymal stem cells.
Klöpper, Jonas Lindenmaier, Werner Fiedler, Ulrike Mehlhorn, Alexander Stark, G Björn Finkenzeller, Günter
Klöpper, Jonas
Lindenmaier, Werner
Fiedler, Ulrike
Mehlhorn, Alexander
Stark, G Björn
Finkenzeller, Günter
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2008-01
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 599.27 KB
Other Titles
Abstract
Survival of ex vivo constructed tissues after transplantation is limited by insufficient oxygen and nutrient supply. Therefore, strategies aiming at improvement of neovascularization of engineered tissues are a key issue in tissue engineering applications. This in vitro study aimed at exploring the usability of osteogenically differentiated human mesenchymal stem cells (MSCs) as carriers of the angiogenic growth factor genes vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) for therapeutic angiogenesis in bone tissue engineering. The ex vivo adenoviral vector mediated transduction into osteogenically differentiated MSCs revealed a highly efficient and long lasting expression of the transgenes. Biological activity of VEGF and Ang-1 secreted from transduced cells was confirmed by analyzing the sprouting, proliferation and apoptosis of human umbilical vein endothelial cells (HUVECs) in response to conditioned medium obtained from transduced cells. The transduced osteogenically differentiated MSCs described in this report may be suitable for inducing neovascularization in bone tissue engineering applications.
Citation
High efficient adenoviral-mediated VEGF and Ang-1 gene delivery into osteogenically differentiated human mesenchymal stem cells. 2008, 75 (1):83-90 Microvasc. Res.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
0026-2862